$0.83
2.10% yesterday
Nasdaq, Dec 05, 10:00 pm CET
ISIN
US74638P1093
Symbol
PPBT

Purple Biotech Ltd - ADR Stock price

$0.83
+0.02 2.85% 1M
-1.78 68.18% 6M
-3.86 82.29% YTD
-3.17 79.24% 1Y
-36.37 97.77% 3Y
-81.86 99.00% 5Y
-569.17 99.85% 10Y
-637.17 99.87% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
-0.02 2.16%
ISIN
US74638P1093
Symbol
PPBT
Industry

Key metrics

Basic
Market capitalization
$7.5m
Enterprise Value
$-2.7m
Net debt
positive
Cash
$10.5m
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
- | -
P/S
- | -
EV/Sales
- | -
EV/FCF
0.4
P/B
0.2
Financial Health
Equity Ratio
88.7%
Return on Equity
-22.0%
ROCE
-15.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-4.8m | -
EBIT
$-5.0m | -
Net Income
$-3.3m | -
Free Cash Flow
$-6.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
69.6% | -
EBIT
68.8% | -
Net Income
72.1% | -
Free Cash Flow
61.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
31.7%
Employees
-
Rev per Employee
-
Show more

Is Purple Biotech Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Financial data from Purple Biotech Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.67 2.67
28% 28%
-
- Research and Development Expense 2.36 2.36
81% 81%
-
-4.84 -4.84
70% 70%
-
- Depreciation and Amortization 0.19 0.19
0% 0%
-
EBIT (Operating Income) EBIT -5.03 -5.03
69% 69%
-
Net Profit -3.25 -3.25
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Purple Biotech Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Purple Biotech Ltd - ADR Stock News

Neutral
GlobeNewsWire
2 days ago
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers      REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resist...
Neutral
GlobeNewsWire
22 days ago
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant ...
Neutral
GlobeNewsWire
about one month ago
Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026 REHOVOT,...
More Purple Biotech Ltd - ADR News

Company Profile

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Gil Efron
Founded 1968
Website purple-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today